Sequence: Stearoyl-AGYLLGKLLKKLAAAALKKLV-NH2
siRNA; splice-switching oligonucleotide (SCO); mRNA
| Experiment Id | EXP000347 |
|---|---|
| Paper | Introducing a Single‑Point Modification to the Cell‑Penetrating Peptide PepFect14 Analogue Sequence |
| Peptide | Val21 |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | medium |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | |
| Peptide Concentration | |
| Rna Concentration | |
| Mixing Ratio | siRNA MR20:1; SCO MR7:1; mRNA CR2:1 and CR3:1 (see Table 2) |
| Formulation Format | nanoparticle (CPP/NA NP) |
| Formulation Components | CPP (PF14/PF14-Lys/analogue) + nucleic acid (siRNA/SCO/mRNA) |
| Size Nm | 78.20 |
| Zeta Mv | 48.00 |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | U87 MG-luc2 (siRNA luciferase); HeLa pLuc-705 (SCO); HaCaT (mRNA) |
| Animal Model | |
| Administration Route | |
| Output Type | reporter modulation (siRNA knockdown / splice correction / mRNA delivery) |
| Output Value | See Table 2: reporter levels vs untreated and vs PF14-Lys |
| Output Units | |
| Output Notes | Table 2: Significant reporter modulation (siRNA knockdown / splice correction / mRNA delivery) compared to untreated and PF14-Lys. |
| Toxicity Notes | Cell viability post-transfection assessed (CCK-8); no significant decrease reported across tested NPs (see Results). |
| Curation Notes |